Clinical trial
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage…
NCT00003715 · AVAX Technologies, Industry · Terminated
Key facts
| NCT number | NCT00003715 |
|---|---|
| Title | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma |
| Official title | A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b |
| Lead sponsor | AVAX Technologies, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa, chemotherapy, cyclophosphamide |
| Enrollment | 425 |
| Start date | Dec 1, 1998 |
| First posted | Apr 23, 2004 |
| Last update posted | Dec 3, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: